Bronchiectasis is one of the most neglected chronic lung diseases despite the fact it impacts 300,000 people in the UK ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

Sue’s recommendation to others living with COPD is to not isolate yourself and stay at home. It is okay to ask for help and ...

In a major positive step for global respiratory health, Member States at the 78th World Health Assembly (WHA), held May 19–27 ...

Breakthrough bioconvergence platform detects inflammatory events prior to symptoms, partnering with Altesa Biosciences to ...

Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...

Bronchiectasis causes your airways, called bronchi, to become damaged and widened over time. When you have bronchiectasis, ...

Columnist Caroline Gainer weighs in on how changes with her doctors have affected her ability to coordinate care for her COPD ...

In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

It is becoming increasingly recognized that people with COPD have an elevated risk of serious CV events,1 discussed Hanania ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.